Loading
Mipletamig is a two-armed protein from Aptevo Therapeutics that holds a leukaemia cell and a T cell together so the T cell kills it. It is in an early trial with standard drugs in newly diagnosed acute myeloid leukaemia.
Mipletamig is a CD123 x CD3 T cell engager from Aptevo Therapeutics. After phase 1 dose escalation and expansion, Aptevo is running RAINIER, a phase 1b/2 dose-optimisation trial started in August 2024 in frontline acute myeloid leukaemia, combining mipletamig with venetoclax and azacitidine in patients unfit for intensive chemotherapy, to set a recommended phase 2 dose. The company reports favourable initial results; they are its own.
1.One arm of Mipletamig binds CD123 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mipletamig" OR ABSTRACT:"Mipletamig" OR TITLE:"APVO436" OR ABSTRACT:"APVO436") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mipletamig, not a curated reading list.
Shares Aptevo Therapeutics and the tag pipeline.
Shares CD123 and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD123 and the tag pipeline.
Shares CD123 and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/